-
![Ben Comer_450x300]( "Commercialization Or Bust?")
Commercialization Or Bust?3/1/2023If you’re a biotech in the earlier stages of clinical development, is it now incumbent upon leadership to build out the capabilities necessary for regulatory submission and commercialization, in case the right deal doesn’t materialize?
-
![Ben Comer_450x300]( "Choosing Your Battles")
Choosing Your Battles2/1/2023Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.
-
![GeoVax Q&A - David Dobbs_450x300]( "With Fundraising, A Track Record Matters: GeoVax's David Dodd")
With Fundraising, A Track Record Matters: GeoVax's David Dodd2/1/2023Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.
-
![Feature - Takeda - Giles Platford_450x300]( "Why Takeda Is Focusing So Much On Plasma-Derived Therapies")
Why Takeda Is Focusing So Much On Plasma-Derived Therapies2/1/2023Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.
-
![Feature - Verve Therapeutics_450x300]( "Verve Therapeutics: How To Build A Gene Editing Biotech")
Verve Therapeutics: How To Build A Gene Editing Biotech1/3/2023Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.
-
![Prix Galien meeting - Peter Marks_450x300]( "Peter Marks: Prioritizing Better Communication And Faster Product Reviews")
Peter Marks: Prioritizing Better Communication And Faster Product Reviews1/3/2023In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.
-
![Ben Comer_450x300]( "The Next Big Thing")
The Next Big Thing1/3/2023Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?
-
![ESG Outlook FEATURE_450x300]( "Executive Outlook: Crafting New Solutions For Persisting Problems")
Executive Outlook: Crafting New Solutions For Persisting Problems12/1/2022Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).
-
![Finance Outlook_FEATURE_450X300]( "Will The Finance And Funding Pendulum Swing Back To Black In 2023?")
Will The Finance And Funding Pendulum Swing Back To Black In 2023?12/1/2022Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.